Date: 2015-04-21
Type of information: IPO
Company: Sensorion (France)
Investors:
Amount: € 8.2 million
Funding type: IPO
Planned used: Sensorion targets all severe inner ear disorders, regarding the treatment of both symptoms and progressive lesions, and is developing three drug candidate programmes to provide a response to currently-unmet medical needs. The funds will be used to finance its clinical trials and preclinical studies, and notably: - A phase 2 study for its SENS-111 product for treating severe bouts of vertigo, for around a third of the proceeds of the Offering; - A clinical pharmacokinetic study and phase 2 study for its SENS-218 product for preventing and treating medium and long-term complications associated with progressive lesions of the inner ear, for around a third of the proceeds of the Offering; - A SENS-300 preclinical programme and clinical pharmacokinetic study for protecting the inner ear from the toxicity of certain drugs, notably within the framework of platinum-based chemotherapy, via the selection of its drug candidate and its reformulation, for around 10% of the proceeds of the Offering. This financing will also support Sensorion\'s innovation efforts associated with its technological platform, for around 10% of the proceeds of the Offering.
The first two drug candidates are currently in or about to enter the clinical trial phase:
- SENS-111, aimed at treating severe bouts of vertigo, is currently in phase 1b and should enter phase 2 during the 1st quarter of 2016;
- SENS-218, aimed at preventing and treating medium and long-term complications associated with progressive lesions of the inner ear, should enter phase 2 during the 3rd quarter of 2016 once its clinical pharmacokinetic file has been completed;
- A third programme, SENS-300, aims to protect the inner ear from the toxicity of certain drugs, notably within the framework of chemotherapy, and thus prevent balance disorders and loss of hearing. This programme is in the final phase for selecting the drug candidate that could enter the Ib clinical phase in 2016. This product portfolio is protected by 7 patent families
Others: * On March 30, 2015, Sensorion, a biotech specialising in the treatment of inner ear diseases, announced that, on March 27, 2015, the Autorité des Marchés Financiers (AMF, the French stock market authority) granted visa n° 15-114 for the prospectus relative to the Company’s shares being listed on the Alternext market in Paris. Shares will be offered within the framework of a general offering, comprising a public offering in France in the form of an open price offer, mainly aimed at individual investors; and a global placement essentially aimed at institutional investors in France and elsewhere (notably excluding the United States). 2,251,408 new shares will be issued within the framework of the Company’s public offering in cash.
Therapeutic area: Otorhinolaryngology
